Press releases

Friday August 30th, 2024
LDC – erfolgreich unter dem Radar
Download PDF
LDC – erfolgreich unter dem Radar

Das einst von der Max-Planck-Innovation gegründete Lead Discovery Center (LDC) agiert als Wirkstoff zentrum wie ein wichtiger Brückenbauer zwischen Akademie und Industrie. | transkript sprach mit Langzeit-CEO Bert Klebl über die Wirkstoff – forschung in Zeiten von Künstlicher Intelligenz und wenig Geld.

Tuesday May 14th, 2024
Icosagen and Lead Discovery Center Announce Collaboration to Discover Novel Monoclonal Antibodies
Download PDF
Icosagen and Lead Discovery Center Announce Collaboration to Discover Novel Monoclonal Antibodies


Tartu, Estonia – May 14th, 2024. Icosagen, a CRDMO with expertise in innovative antibody research and production, announces a strategic partnership on selected projects with Lead Discovery Center GmbH (LDC), a translational drug discovery organization tapping on a broad network in academia and industry. This alliance is focused on the discovery of monoclonal antibody portfolios targeting therapeutically relevant proteins, including a pivotal G-protein coupled receptor (GPCR), which are often challenging to address.

continue

Scope of Collaboration

Antibody-based inhibitors have gained  relevance in the field of drug discovery due to their exceptional affinity, selectivity and physicochemical properties. Within this collaboration, Icosagen will generate, identify, and discover potent antibodies against innovative and therapeutically relevant targets, supplying them to LDC for further development.

Utilizing its proprietary technology, Icosagen will produce the proteins of interest and enhance their display on the surface of virus-like particles, which serve as vehicles for the production of antibodies with affinity for the targets. Subsequently, an extensive library will be established to facilitate the selection of high-affinity monoclonal antibodies, which will undergo further analysis at LDC through a streamlined process of high-throughput screening. This partnership highlights Icosagen’s capability to scale its proprietary platforms and synergize effectively with LDC’s workflow.

“Partnering with LDC will further help expand the opportunities for antibody therapeutics, especially in the challenging field of GPCR-targeted treatments” said professor Mart Ustav, CEO of Icosagen. “This will not only highlight our technological expertise but also perfectly aligns with our mission to transform scientific discoveries into life-changing treatments.”

“We are excited to partner up with Icosagen, a competent and highly experienced player in the field of antibody research” remarked Bert Klebl, CEO and CSO of LDC. “This project will greatly benefit from Icosagen’s expertise and state-of-the-art capabilities as we pursue our shared goal: the development of novel therapeutics that can make a meaningful difference in healthcare.”

Future Prospects

LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals as well as candidate nomination. In close collaboration with high-profile partners from research and industry, LDC is building a strong and growing portfolio of small molecule and antibody leads with exceptional medical and commercial potential. The partnership between Icosagen and LDC holds promise in advancing targeted therapeutics, with the potential to revolutionize treatment approaches and improve outcomes for patients worldwide. The successful development of these monoclonal antibodies is anticipated to significantly advance the understanding and treatment of diseases.

###

About Icosagen

Icosagen is a renowned biotech company with over 20 years of experience in pioneering antibody research and production. With a strong commitment to innovation, Icosagen has developed a range of proprietary platforms for the efficient discovery, development and manufacturing of high-quality antibodies, serving the global research community and pharmaceutical industry.

Further information available at: www.icosagen.com

About LDC

Lead Discovery Center GmbH (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals as well as candidate nomination. In close collaboration with high-profile partners from research and industry, LDC is building a strong and growing portfolio of small molecule and antibody leads with exceptional medical and commercial potential.

LDC sustains a long-term partnership with the Max Planck Society and its institutes as well as with KHAN-I, and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, InvIOS, Novo Nordisk, Cumulus Oncology, Nodus Oncology, JT Pharmaceuticals, KinSea Lead Discovery AS, HLB Pharma, the Helmholtz Center for Infection Research, e.g. In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation.

Further information available at: www.lead-discovery.de

###

Contact:

Lead Discovery Center GmbH
Otto-Hahn-Straße 15
44227 Dortmund, Germany
pr@lead-discovery.de
www.lead-discovery.de

###

Thursday April 25th, 2024
Norwegian Start-up KinSea Announces First Closing of Seed Financing
Download PDF
Norwegian Start-up KinSea Announces First Closing of Seed Financing
  • Equity investments from KHAN Technology Transfer Fund I and Berners AS
  • Funds will be used to further advance KinSea’s lead program, a highly differentiated FLT3 kinase inhibitor for the treatment of acute myeloid leukemia (AML), including hard-to-treat, drug-induced, and drug-resistant mutations
  • This capital increase supports KinSea’s strategy to unlock the potential of marine bioactives for the treatment of cancer and other diseases with significant unmet medical needs
continue

Tromsø, Norway, and Dortmund, Germany – April 25th, 2024. KinSea Lead Discovery AS, a biopharmaceutical start-up pioneering the use of marine bioactives for the treatment of human diseases, announces the successful first closing of its seed financing round. It includes an equity investment from KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I), an early-stage life sciences venture fund based in Germany, and welcomes the new investor Berners AS, a North Norwegian investment company. A year ago, KinSea had already secured a convertible loan from KHAN-I, which was recently converted into shares.

The financing enables the company to further develop its lead program, a FLT3 kinase inhibitor based on unique chemistry from marine sources, towards preclinical and clinical testing. Data from in vivo proof-of-concept studies suggest superior properties over existing FLT3 inhibitors, including potential broad activity against known drug-induced and drug-resistant FLT3 mutations, improved selectivity, and outstanding in vivo potency. The program originates from the successful collaboration of the founding partners, Arctic University of Norway (UiT), University of Bergen (UiB), Norinnova, and Lead Discovery Center GmbH (LDC).

‘We are grateful for the continued confidence and support from KHAN-I, and delighted to welcome Berners AS on board’, says Jeanette Hammer Andersen, CEO of KinSea. ‘This first closing validates the transformative potential of our approach. We are very committed to take our FLT3 inhibitors through the next stages of drug discovery and development in order to provide entirely new treatment options for AML patients that are safer and more effective’.

KinSea also plans to gradually expand its drug discovery pipeline and establish a diversified portfolio of high-potential drug candidates based on novel chemical scaffolds from the Arctic Ocean for the treatment of cancer and other diseases.

‘We are excited to reaffirm our commitment to KinSea and its groundbreaking work in the field of marine-derived therapeutics. The team has made significant progress over the last year, and we are convinced that their unique approach and capable team will continue to drive the maturation and expansion of their pipeline, and eventually make a meaningful impact on patients’ lives, in particular with regard to urgently needed, improved therapies for AML patients’, comments Bert Klebl, Managing Director of KHAN-I.

Mats Sæverud, CEO of Berners AS, adds: ‘In KinSea, we found an ambitious startup company that wants to make an important impact by employing natural products from the Arctic Ocean. The KinSea team has bold visions, scalable solutions, excellent expertise and skills, and fits well with Berners´ ambitions.’

KinSea has already started discussions with further investors for a second and final closing.

###

Contact
Lead Discovery Center GmbH
Otto-Hahn-Straße 15
44227 Dortmund
Germany
Phone: +49 231 97 42 70 00
Mail: pr@lead-discovery.de

###

About KHAN-I

KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I) is an early-stage life sciences venture fund with €70 million under management. Our mission is to create value through cooperative drug development partnerships with academic innovators in Europe. KHAN-I focuses on first-in-class therapies for attractive markets with a high unmet medical need. The fund is managed by Khanu Management GmbH, an experienced team of professionals with proven track records in early-stage drug development and academic spin-offs as well as pharma licensing and partnering. KHAN-I received an investment from the European Investment Fund (EIF) with the support of InnovFin Equity, and with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (“EFSI”) under the Investment Plan for Europe. KHANI is also supported by Austria Wirtschaftsservice GmbH (AWS with funds provided by the Austrian

Federal Ministry for Digital and Economic Affairs and the Austrian Foundation for Research, Technology, and Development), Max Planck Foundation, and Thyssen’sche Handelsgesellschaft mbH. In addition, KHAN-I sustains a preferred partnership with the Max-Planck Society (Max-Planck Gesellschaft e.V.).

Further information at www.khanu.de

About Berners AS

Berners AS is a newly established, privately owned investment company, based in Tromsø, Norway. Through investments and active ownership, Berners will contribute to the development of profitable and sustainable businesses, especially within the seafood and marine sector. We aim to be a supporter of the development of brands and competence clusters in Northern Norway. Our investment strategy is based on our knowledge and love for the coast and the sea, and the opportunities that exist there. Berners is owned by Triko AS (80%) and Larren Invest AS (20%).

About Norinnova

Norinnova is one of Northern Norway’s most competent and experienced agencies for research commercialization. Norinnova connects researchers, start-up environments, companies and commercial actors to develop and utilize the region’s innovation power. For more than 30 years, Norinnova has worked closely with researchers and leading research communities in Northern Norway to harness the power of innovation in this region. This collaboration has contributed to the creation of brand-new businesses and has reinforced existing companies through new products and services. Norinnova secures rights, helps provide funding, investigates market potential, finds relevant partners, and contributes so that the scientists can get their product or service to the market.

Further information available at: www.norinnova.no

About LDC

Lead Discovery Center GmbH (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals as well as candidate nomination. In close collaboration with high-profile partners from research and industry, LDC is building a strong and growing portfolio of small molecule and antibody leads with exceptional medical and commercial potential.

LDC sustains a long-term partnership with the Max Planck Society and its institutes as well as with KHAN-I, and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, InvIOS, Novo Nordisk, Cumulus Oncology, Nodus Oncology, JT Pharmaceuticals, KinSea Lead Discovery AS, HLB Pharma, the Helmholtz Center for Infection Research, e.g. In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation.

Further information available at: www.lead-discovery.de

Thursday September 12th, 2019
Investment Plan for Europe – Successful launch of Tech Transfer Fund “KHAN-I”
Download PDF

Investment Plan for Europe – Successful launch of Tech Transfer Fund “KHAN-I”

Khanu Management GmbH (Khanu), a drug discovery focused fund management team, announces the successful launch of KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I), based in Dortmund, Germany.
The European Investment Fund (EIF, Luxemburg), the Austria Wirtschaftsservice GmbH (Vienna, Austria) and the Max Planck Foundation (Munich, Germany) committed in a first closing an investment of a total volume of € 60 million into KHAN-I for a period of 5 plus 2 years in early-stage drug discovery projects. The Khanu fund management team will invest a minority amount.

continue

Dortmund, September 12, 2019 – Khanu Management GmbH (Khanu), a drug discovery focused fund management team, announces the successful launch of KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I), based in Dortmund, Germany.

The European Investment Fund (EIF, Luxemburg), the Austria Wirtschaftsservice GmbH (Vienna, Austria) and the Max Planck Foundation (Munich, Germany) committed in a first closing an investment of a total volume of € 60 million into KHAN-I for a period of 5 plus 2 years in early-stage drug discovery projects. The Khanu fund management team will invest a minority amount.
The EIF will provide up to € 30 million through “InnovFin Equity Facility for Early Stage” (IFE), an integral part of the European growth initiative. The investment is supported by the Juncker Plan’s European Fund for Strategic Investments (EFSI).

Projects are sourced predominantly from academia in Germany and Austria, focussing on innovative therapeutic opportunities in indications with high unmet medical need. KHAN-I will invest into either innovative project ideas covered by collaboration agreements or into start-up vehicles. The Lead Discovery Center GmbH, Dortmund (LDC), a professional drug discovery and translational research incubator originally founded by Max-Planck-Innovation GmbH (MI) with a proven track record (www.lead-discovery.de) will provide its drug discovery services to incubate these novel project hypotheses, where applicable.
To facilitate professional translation in life sciences in Austria, KHAN-I has founded Vienna-based wings4innovation GmbH (w4i) for scouting and executing promising drug discovery projects on behalf of KHAN-I and Khanu. The Partnership is supported by aws with funds provided by the Austrian Federal Ministry for Digital and Economic Affairs and the Austrian Foundation for Research, Technology and Development (NFTE).
KHAN-I also signed a co-investment agreement with the Max Planck Gesellschaft e.V. (MPG), Germany´s largest basic research organisation, adding € 18 million of co-funding for drug discovery projects originating from the world class biomedical research of the Max Planck Institutes.
“With KHAN-I, we have realised a unique and powerful translational vehicle, combining successful players in the field”, summarizes Bert Klebl, one of the three managing directors of Khanu and managing director of LDC. “The line-up of the (co-) investors is both, acknowledgement of the professional and successful performance in the past decade, where we opened a new chapter in the book of German translational research with the inception of LDC by MPG and its collaborative drug discovery and development approach as well as confidence in the game-changing capabilities of this unique translational concept. With KHAN-I, Khanu, LDC and w4i, we want to get to the next level and multiply the commercial successes in early drug discovery in view of a true benefit for all patients out there.”
European Commissioner Carlos Moedas, responsible for Research, Science and Innovation, said: “Today’s agreement adds to the Juncker Plan’s strong track record in supporting biomedical research and drug discovery projects. This kind of support for researchers and scientists to bring their ideas and innovations to market will help keep Europe at the forefront of innovation.”

EIF Chief Executive Pier Luigi Gilibert comments: “KHAN-I will be one of the pioneers to develop the tech transfer segment in the German and Austrian life sciences venture capital ecosystem. Without such funding, these innovations would not reach a maturity level high enough for attracting other investors or strategic acquirers. Our cooperation with KHAN-I and its investment approach is an excellent example for the achievement of EU policies to strengthen the discovery and development of new pharmaceuticals for the benefit of the people in Europe.”
„The life-science-industry plays an essential role within Austria’s economy. Due to the new fund, we create new jobs and support a stronger and successful life-science-sector. As a result, KHAN-I is an inevitable measure to strengthen the international competitiveness of Austria’s life-science-industry”, says Elisabeth Udolf-Strobl, Minister for Digital and Economic Affairs of the Republic of Austria.
“Based on the co-investment agreement between MPG and KHAN I we are able to continue our very fruitful drug discovery partnership with LDC established over more than a decade and hope to generate additional treatment options for patients and return potential for both MPG and KHAN I” adds Ulrich Mahr, Member of the General Management of Max-Planck-Innovation GmbH, the technology transfer office of the MPG.
###
Contact Khanu
Dr. Michael Hamacher, hamacher@khanu.de, tel. +49 231 9742 7000

Contact EIF
Christof Roche, c.roche@eib.org, tel.: +352 43 79 89013 / Mobile: +32 479 65 05 88
Website: www.eib.org/press – Press Office: +352 4379 21000 – press@eib.org

About EIF
The European Investment Fund (EIF) is part of the European Investment Bank Group. Its central mission is to support Europe’s micro, small and medium-sized businesses (SMEs) by helping them access finance. EIF designs and develops venture and growth capital, guarantees and microfinance instruments which specifically target this market segment. In this role, EIF fosters EU objectives in support of innovation, research and development, entrepreneurship, growth, and employment. More information on EIF’s work under EFSI is available at www.eif.org.

About the Juncker Plan
The Investment Plan for Europe, the so-called “Juncker Plan”, is one of the European Commission’s top priorities. It focuses on boosting investments to create jobs and growth by making smarter use of new and existing financial resources, removing obstacles to investment and providing visibility and technical assistance to investment projects. The European Fund for Strategic Investments (EFSI) is the central pillar of the Juncker Plan. It provides a first loss guarantee, allowing the EIB to invest in more, often riskier, projects. The projects and agreements approved for financing under the EFSI so far are expected to mobilise almost € 424 billion in investments and support around 967,000 SMEs across all 28 Member States.

About “InnovFin Equity”
InnovFin Equity – managed by EIF – is in integral part of the European growth initiative “InnovFin – EU Finance for Innovators”, a program launched by the European Commission and the EIB Group in the framework of Horizon 2020. Via InnovFin Equity, EIF provides equity investments and co-investments to or alongside funds focusing on companies in their pre-seed, seed, and start-up phases operating in innovative sectors covered by Horizon 2020, including life sciences, clean energy and high-tech. Under InnovFin Equity, EIF targets investments in around 45 funds, mobilising a total amount of € 4-5 billion to be invested in enterprises located or active in the EU and Horizon 2020 Associated Countries.
About aws
Austria Wirtschaftsservice GmbH (aws) is the Austrian government promotional bank. aws offers Austrian companies financial assistance in the form of loans, guarantees, grants and equity as well as consultancy services from the start-up to expansion phase. Innovative SMEs wishing to apply for finance under the InnovFin programme can directly contact aws under the following website https://www.aws.at/en/
About Max-Planck-Förderstiftung
The Max-Planck Foundation is a private, independent and non-profit organisation with the sole purpose of providing funds for excellent, innovative and forward-looking research projects of the Max Planck Society. The   foundation was established in 2006 and the capital of the foundation is currently around € 500 million.
About Max-Planck-Innovation
Max-Planck-Innovation is responsible for the technology transfer of the Max Planck Society and, as such, the link between industry and basic research. With our interdisciplinary team we advise and support scientists of the Max Planck Institutes in evaluating their inventions, filing patents and founding companies. We offer industry a unique access to the innovations of the Max Planck Institutes. Thus, we perform an important task: the transfer of basic research results into products, which contribute to the economic and social progress.
About KHAN-I
KHAN-I is a limited partnership under German law with the European Investment Fund (EIF), Max Planck Foundation (MPF), Austria Wirtschaftsservice GmbH (AWS), and KHAN I Vermögensverwaltung GmbH & Co. KG as non-managing limited partners and Khanu Management GmbH (KHANU) as general partner and fund manager. The purpose of KHAN-I is to invest in innovative drug discovery projects and spin-out companies, primarily originating from academic sources, at the discovery, pre-clinical and clinical development stage for human healthcare and, opportunistically, veterinary care as well as to commercialise the results and products of the investments and, thus, to participate, directly or indirectly, in future proceeds.

Friday April 12th, 2019
A PhD’s guide on how to organize a conference
Click here

A PhD’s guide on how to organize a conference

Eleven Early Stage Researchers from eight different institutions including the LDC, all part of the EU DivIDE network, tell us about their experience organizing their first international conference – and what they learned on the way.

continue

Eleven Early Stage Researchers from eight different institutions including the LDC, all part of the EU DivIDE network, tell us about their experience organizing their first international conference – and what they learned on the way.

Tuesday April 2nd, 2019
LDC and Korean Drug Development Fund collaborate to mature innovative drug discovery projects in South Korea
Download PDF

LDC and Korean Drug Development Fund collaborate to mature innovative drug discovery projects in South Korea

Seoul, South Korea. The Lead Discovery Center (LDC) and the Korean Drug Development Fund (KDDF) have entered into an agreement to facilitate the interaction between LDC and the prospering South Korean biotech scene.

continue

April 2, 2019 Dortmund, Germany – Seoul, South Korea. The Lead Discovery Center (LDC) and the Korean Drug Development Fund (KDDF) have entered into an agreement to facilitate the interaction between LDC and the prospering South Korean biotech scene. The aim of the collaboration is to facilitate the licensing of assets from LDC’s innovative R&D pipeline to South Korean biotechs, who will then advance the projects into the clinic. KDDF will assist LDC in identifying such entities and hopes to support the respective biotechs financially once a licence deal has been concluded. By attracting highly innovative assets, KDDF is substantially and sustainably stimulating the Korean drug discovery community, creating an investor-friendly climate.

The collaboration agreement between KDDF and LDC was signed during this year´s Global C&D partnering conference in Seoul in February.
“We are delighted to intensify our interaction with the biotech community in South Korea. The LDC has already closed three licensing deals with South Korean biotechs, so we are now building on these inroads into South Korea’s drug discovery ecosystem to the benefit of our partners. In collaboration with the KDDF, we hope to broaden our existing relationship and increase the number of innovative assets licensed to South Korean biotechs. The goal is to better advance LDC early drug discovery assets to the clinic,” commented Bert Klebl, CEO and CSO of the LDC.

About the KDDF
Established in September 2011, the Korea Drug Development Fund (KDDF), a consortium of three health-related Korean Ministries – the Ministry of Science, ICT, and Future Planning; the Ministry of Trade, Industry, and Energy; and the Ministry of Health and Welfare – is a government-initiated drug development program, which aims to transform Korea into a global leader for new drug development and to enhance national competitiveness in the global arena.
In the first phase of the project, KDDF focused on building its own business portfolio and process that is essential to global drug development. In consequence, this helped us establish a top-notch screening system for numerous research and development (R&D) projects, coupled with a successful milestone-based output management system. In the subsequent second phase of the project, KDDF further materialized its innovation-driven portfolio management strategy through a newly introduced joint R&D program with global Big Pharma, the actual developers who aspire to commercialize early stage assets, and continued to expand its support in the Research & Business Development (R&BD) field.

Friday March 29th, 2019
LDC Receives the City of Dortmund Business Award
Download PDF

LDC Receives the City of Dortmund Business Award

The Lead Discovery Center (LDC) has won Dortmund’s Business Prize, awarded yearly by the Wirtschaftsförderung and the Sparkasse Dortmund. The distinguished jury selected the LDC for its innovative business concept and its outstanding achievements for the benefit of society. The company forms a vital link between academia and industry. In close collaboration with both partners, it helps transform great ideas into medicines that can change the lives of millions of people.

continue

March 29, 2019, Dortmund, Germany – The Lead Discovery Center (LDC) has won Dortmund’s Business Prize, awarded yearly by the Wirtschaftsförderung and the Sparkasse Dortmund. The distinguished jury selected the LDC for its innovative business concept and its outstanding achievements for the benefit of society. The company forms a vital link between academia and industry. In close collaboration with both partners, it helps transform great ideas into medicines that can change the lives of millions of people.

Since it was founded in Dortmund 11 years ago, the LDC has initiated 79 drug discovery projects, each one targeting a severe unmet medical need. The portfolio covers common conditions such as cancer and infections, as well as rare diseases frequently neglected by industry. 15 projects have progressed into co-development or licensing partnerships with industry.

“The award highlights the exceptional commitment of our team and our partners, both in academia and industry. Their expertise and energy has enabled us to get that many projects off the ground,” said Dr Bert Klebl, CEO of the LDC. “We are proud to be part of Dortmund’s innovation ecosystem and grateful for the collaborative spirit we have enjoyed here over the past decade.”

Last year, the LDC opened a subsidiary in Munich for the development of therapeutic antibodies. Altogether, the LDC has created over 75 qualified jobs, most of them at their headquarters in Dortmund.

“Dortmund has always been a superb location for the LDC providing easy access to a high-tech infrastructure and great support from the local network around the TZDO and Sparkasse Dortmund”, Klebl added.

Tuesday February 19th, 2019
New Center of Competence for Innovative Diabetes Therapy (KomIT) is funded by NRW and EU

New Center of Competence for Innovative Diabetes Therapy (KomIT) is funded by NRW and EU

The Lead Discovery Center (LDC) is part of a new consortium of eight partners from industry and academia focusing on the development of new diabetes therapies.

continue

Februar 19, 2019, Dortmund, Germany – The Lead Discovery Center (LDC) is part of a new consortium of eight partners from industry and academia focusing on the development of new diabetes therapies. During the next three years, a new Center of Competence will be established at the German Diabetes Center (DDZ) based on a total funding of about 3.5 Mio Euro provided by Northrhine-Westphalia and the EU. This center is coordinated by DDZ and aims at efficient translation of new research results into clinical application, finally improving therapeutic options for diabetic patients.

The continuous rise in the number of diabetic patients in Germany and the associated socio-economic burden for the health system urgently require the development of new causal therapies. “Together with our partners we aim to establish a sustainable infrastructure, to bring innovative approaches of diabetes therapy rapidly and directly to the patients” explains Prof. Michael Roden, scientific Director of the German Diabetes Center and coordinator of the new Center of Competence for Innovative Diabetes Therapy (KomIT). “Our joint activities aim to bundle expertise, finally leading to scientific and technological break-throughs in diabetes research”. In addition to the LDC and DDZ, the other partners are: Algiax Pharmaceuticals GmbH, Taros Chemicals GmbH & Co. KG, vivo Science GmbH, A & M Labor für Analytik und Metabolismusforschung Service GmbH, PROFIL Institut für Stoffwechselforschung GmbH, and TU Dortmund with the Drug Discovery Hub Dortmund (DDHD).

In Northrhine-Westphalia, excellent basic research in the field of clinical-experimental diabetes studies is conducted for a long time. However, translation of these results into clinical applications is not yet sufficient to generate an economic boost. For start-ups and small companies with high innovation potential it is often not possible to carry out extensive experimental and clinical research with sufficient critical mass. At this point, the new Center of Competence provides strategic support. Leading idea is to build up a sustainable infrastructure that combines expertise from management, medicinal chemistry, preclinical and analytical studies, toxicology and physiology, up to clinical testing.

This novel research infrastructure provides a strong boost for the pharma and biotech sector in Northrhine-Westphalia and supports innovation and competitiveness in NRW. The project is funded within the program “EFRE.NRW – Investitionen in Wachstum und Beschäftigung” supported by NRW and the Europen Union.

https://www.efre.nrw.de

Tuesday January 8th, 2019
LDC and European-Canadian Consortium Attract €1.1 Million to Develop new Therapies Against Rare Disease ATD
Download PDF

LDC and European-Canadian Consortium Attract €1.1 Million to Develop new Therapies Against Rare Disease ATD

The Lead Discovery Center (LDC) has teamed up with McGill University in Canada, Institut National de la Santé Et de la Recherche Médicale (INSERM) in France and Semmelweis University in Hungary to discover new approaches for the treatment of alpha-1 antitrypsin deficiency (ATD), a rare genetic disorder that lead to severe lung and liver diseases. The partners receive a total of €1.1 million in funding under the transnational E-Rare-3 programme on rare diseases.

continue

January 08, 2019, Dortmund, Germany – The Lead Discovery Center (LDC) has teamed up with McGill University in Canada, Institut National de la Santé Et de la Recherche Médicale (INSERM) in France and Semmelweis University in Hungary to discover new approaches for the treatment of alpha-1 antitrypsin deficiency (ATD), a rare genetic disorder that lead to severe lung and liver diseases. The partners receive a total of €1.1 million in funding under the transnational E-Rare-3 programme on rare diseases.

ATD is caused by mutations of alpha1-antitrypsin (A1AT), an enzyme that is primarily produced in the liver and normally transported to the lung where it helps maintain organ health and function. Genetic alterations lead to misfolded proteins which can no longer be secreted. In the lung, the absence of functional A1AT can lead to critical disorders such as chronic obstructive pulmonary disease (COPD). In the liver, the accumulation of mutant A1AT can cause liver fibrosis, cirrhosis and subsequently hepatic failure. To date, there is no effective pharmacological treatment for ATD.

This project builds on ground-breaking results of project partner Eric Chevet and his team at INSERM y that provide a novel, highly promising target for ATD treatment. They have shown that the activation of a certain enzyme, IRE1, triggers the release of fully functional ZA1AT from the liver. ZA1AT is the most frequent mutant form of A1AT. The project partners will work together to identify and develop small molecules that can rescue active ZA1AT via IRE1-modulation. The objective is to establish a lead compound series with favourable drug-like properties and proof-of-concept in in-vivo models within three years.

The partnership builds on highly productive existing collaborations between the players and leverages their complementary strengths and capabilities. The teams of McGill University and INSERM contribute leading expertise in the underlying biology of protein misfolding diseases in general, and A1AT and IRE1 function in particular, while the teams of Semmelweis University and LDC bring in world-class medicinal chemistry know-how and infrastructure (incl. pharmacology), together with a proven track record in drug discovery from target level through to proof-of-concept. The project also gains support from leading clinicians and patient organizations committed to finding a cure for ATD and to improving the lives of people affected worldwide.

“This is a unique and truly powerful constellation,” says Bert Klebl, managing director of the LDC. “With our combined expertise and commitment, we are perfectly positioned to advance this project and make a difference to the lives of patients suffering from this rare and widely under-recognized disease.”